Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Not Yet Recruiting NCT05610956

Evaluate the Possible Efficacy and Safety of Empagliflozin in Patient With Ulcerative Colitis

Conditions: Ulcerative Colitis

Sex: All
Ages: 18 Years – 70 Years
Phase: EARLY_PHASE1
Enrollment: 60
Sponsor: Tanta University

Summary

•This study will be a randomized, controlled, parallel study. .To demonstrate the efficacy of empagliflozin and clinical improvement in patients of mild to moderate UC using the Montreal classification of severity of ulcerative colitis.

Eligibility Criteria

Inclusion Criteria:•Patients with mild to moderate UC are diagnosed by history, clinical signs according to the Montreal classification of severity of ulcerative colitis and( Endoscopy, and biopsy) to establish the chronicity of inflammation and to exclude other causes of colitis.Exclusion Criteria:Other inflammatory bowel diseases (CD).History of serious hypersensitivity to empagliflozin or any component of the formulation.Patients on dialysis.Severe renal impairment (eGFR <20 ml/minute/1.73m2) .Chronic urinary tract infection.Chronic genital infection.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05610956). StuddyBuddy aggregates publicly available trial information.